This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT05814107 |
|---|---|
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | Carmot Australia First Pty Ltd |
| Enrollment | 94 participants |
| Design | Interventional, Randomized, Sequential, Masking: Double |
| Conditions | Type 2 Diabetes; Overweight or Obesity |
| Interventions | CT-996; Placebo |
| Start | May 9, 2023 |
| Primary completion | Nov 7, 2025 |
| Study completion | Nov 7, 2025 |
| Results posted | Not yet |
| Registry last updated | Nov 28, 2025 |
| Collaborators | Carmot Therapeutics, Inc.; Hoffmann-La Roche |
Compounds on this site that cite this trial
What the registry says the trial is about
This study is designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with Type 2 Diabetes Mellitus (T2DM).
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Incidence of Treatment-Emergent Adverse Events | From first study drug administration until last safety follow-up (up to 31 days [Part 1] or 58 days [Parts 2 and 3]) |
12 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
